Neurology® Podcast

The Delayed Recall episode for June takes a look at recent guidelines and developments in the field of multiple sclerosis treatment. In the first interview, Dr. Stacey Clardy and Dr. Alexander Rae-Grant discuss recent practice guidelines for multiple sclerosis, and talk about Dr. Rae-Grant's paper regarding these guidelines. This interview first aired on April 24, 2018. The second interview, from the May 15, 2018 episode, features Dr. Clardy speaking with Dr. Riley Bove about her recent paper on rituximab treatment during pregnancy. Next, hear Dr. Clardy speak with Dr. Raed Alroughani about relapse occurrence of MS during pregnancy, in an interview that appeared in the March 6, 2018 episode. In the conclusion to this month's episode, Dr. Mark Keegan and Dr. Gavin Giovannoni discuss the topic of alemtuzumab treatment for multiple sclerosis patients. This interview first appeared on April 18, 2017.

Dr. Roy Strowd talks with Dr. Saman Zafar about her paper on amateur fundus photography.

1. Featured Article: ABBY: A Phase 2 randomized trial of crenezumab in mild-to-moderate Alzheimer's Disease2. What's Trending: Epilepsy Birth Control Registry This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 22, 2018, print issue of Neurology. In the first segment, Dr. Jeff Burns talks with Dr. Jeffrey Cummings about results from the ABBY clinical trial on crenezumab as a potential treatment for mild to moderate Alzheimer Disease. For the "What's Trending" segment, Dr. Katherine Zarroli interviews Dr. Andrew Herzog about the Epilepsy Birth Control Registry (http://www.epilepsybirthcontrolregistry.org).

1. Featured Neurology® Clinical Practice Article: Ask a Neurologist: What Primary Care Providers ask, and reducing referrals through eConsults2. What's Trending: Update on arboviruses This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 15, 2018, print issue of Neurology. In the first segment, Dr. Heather Harle interviews Drs. Ana Bradi and Erin Keely about their paper on implementing an eConsult service between primary care providers and neurologists at the Ottawa Hospital. For the "What's Trending" segment, Dr. Amanda Piquet and Dr. Daniel Pastula discuss what every neurologist should know about mosquito- and tick-borne disease. DISCLOSURES: Dr. Harle and Dr. Bradi report no disclosures. Dr. Keely served as Associate Editor for Obstetric Medicine (2010 - 2017); and has received research support from CIHR (Partnerships for Health System Improvement, 367535 and 358003), Stemmler Medical Education Research Fund, and National Board of Medical Examiners, and Physicians' Services Incorporated Foundation. Dr. Piquet and Dr. Pastula report no disclosures.

1. Featured Article: Factors associated with treatment delays in pediatric refractory convulsive status epilepticus2. What's Trending: Focused ultrasound for treating tremorThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 8, 2018 issue of Neurology. In the first segment, Dr. Erika Axeen talks with Dr. Iván Fernández about his paper on factors that influence treatment delays in pediatric refractory convulsive status epilepticus. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Jeff Elias on two recent articles published in the New England Journal of Medicine regarding focused ultrasound treatment for tremor. DISCLOSURES: Drs. Axeen and Crowell report no disclosures. Dr. Fernández has received research support from Epilepsy Research Fund, Fundación Alfonso Martín Escudero (Grant for the study of Epileptic Encephalopathies), and HHV6 Foundation. Dr. Elias reports grant support from InSightec, the BIRD Foundation, and the Focused Ultrasound Foundation.

This month's Delayed Recall episode includes interviews on topics that were highlighted in the Neurology Today "Best Advances of 2017" editorial. The episode starts with Dr. Andy Southerland's interview with Dr. Joseph Safdieh (April 10, 2018) that features a few editor's pick from the Best Advances in neurology in 2017. Following this clip, we have the full-length interview from the February 28, 2017 episode where Dr. Ted Burns speaks with Dr. Richard Finkel about nusinersen and spinal muscular atrophy. Next, in an interview from the February 13, 2018 podcast, Dr. Tesha Monteith focuses her interview with Dr. Peter Goadsby on CGRP treatments and migraine. In the third and final interview, Dr. Nicole Chiota-McCollum and Dr. Greg Albers regarding the DEFUSE trial results, which first aired in the April 17, 2018 episode of the podcast.

1. Featured Article: Baseline symptoms and basal forebrain volume predict future psychosis in early Parkinson disease2. What's Trending: Drug pricing This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 1, 2018, print issue of Neurology. In the first segment, Dr. Jeff Ratliff talks with Dr. Matthew Barrett about his paper on predictors of psychosis in Parkinson disease. For the "What's Trending" segment, Dr. Ted Burns discusses drug pricing with journalist Ike Swetlitz.DISCLOSURES: Dr. Ratliff has received a speaker honorarium from Haverford College. Dr. Barrett has received research support from Axovant Sciences, Inc. (clinical trial site PI), Azevan Pharmaceuticals (clinical trial site PI), Merck Sharp & Dohme Corp. (Clinical trial site PI), Biogen (clinical trial site PI), Virginia Center of Alzheimer´s and Related Diseases Research Award Fund (PI), U.S. Department of Defense Neurotoxin Exposure Treatment Parkinson's Research Career Progress Award (PI), and NIH (clinical trial site PI).Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring. Mr. Swetlitz is a reporter for StatNews.

1. Featured Article: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis2. What's Trending: Global, regional, and national burden of neurological disorders during 1990–2015 (from Lancet Neurology)This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 24, 2018, print issue of Neurology. In the first segment, Dr. Stacey Clardy talks with Dr. Alexander Rae-Grant about the AAN Practice Guideline on disease-modifying therapies for adults with multiple sclerosis. For the "What's Trending" segment, Dr. Jason Crowell interviews Dr. Theo Vos about findings from the Global Burden of Diseases, Injuries, and Risk Factors Study and the growing need for clinicians with neurologic expertise.DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Rae-Grant has served on the Neurology Evidence Review Team, 2011-2018; receives publishing royalties from Handbook of Multiple Sclerosis (Springer Healthcare, 2010), Comprehensive review of clinical neurology, (Wolters Kluwer, 2012), 5 minute consult in neurology (Wolters Klower, 2012), Comprehensive review of clinical neurology second edition ( LWW, 2016), Ultimate review of neurology (DEMOS 2016), and Multiple Sclerosis and Related disorders (DEMOS, 2014); edits neurology chapters for Dynamic Medical, an online text book of medicine which is funded via library subscriptions; was involved in a clinical trial of biotin for multiple sclerosis with MedDay (no personal remuneration); and receives research support from NIH (grant #A6022304). Dr. Crowell reports no disclosures.

1. Featured Article: Clinical Reasoning: A young woman with symmetric weakness and behavioral disturbance2. What's Trending: DEFUSE 3 trial results on thrombectomy vs. standard therapy alone for ischemic stroke This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 17, 2018, print issue of Neurology. In the first segment, Dr. Dan Ackerman talks with Dr. Jon Rosenberg about the differential diagnosis of a young patient with symmetric weakness, behavioral changes, and bilateral infarcts. For the "What's Trending" segment, Dr. Nicole Chiota-McCollum speaks with Dr. Gregory Albers about findings from the DEFUSE 3 clinical trial.DISCLOSURES: Dr. Ackerman, Dr. Rosenberg, and Dr. Chiota-McCollum report no disclosures. Dr. Albers has served on a steering committee for Lundbeck and Covidien; serves on the editorial board for Stroke; holds a patent for RAPID software for MRI and CTP analysis of diffusion and perfusion data; has consulted for Astra Zeneca, Biogen, and iSchemaView; holds stock in iSchemaView; and has received research support from NINDS.

1. Featured Article: Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD2. Neurology Today: Top research advances in 2017This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 10, 2018, print issue of Neurology. In the first segment, Dr. Stacey Clardy interviews Dr. Riley Bove about her paper on rituximab treatment before and during pregnancy in patients with multiple sclerosis and NMOSD. For the second segment, Dr. Andy Southerland speaks with Dr. Joseph Safdieh on the Neurology Today editorial selections for the top research advances in 2017.DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR).Dr. Southerland serves as Podcast Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: "Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;" and gave legal expert review. Dr. Safdieh has served on scientific advisory board for Upsher Smith; receives publishing royalties from Rubin MP, Safdieh JE. Netters Concise Neuroanatomy (Elsevier 2007); and serves as Editor-in-Chief of Neurology Today.

1. Featured Article: The Mitochondrial Disease Patients' Diagnostic Odyssey: Results of A Survey2. What's Trending: Teen concussion and early tauopathyThis Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 3, 2018, print issue of Neurology. In the first segment, Dr. Jason Crowell talks with Drs. John L.P. Thompson and Michio Hirano about their Neurology: Genetics paper on the long journey to diagnosis for patients with mitochondrial disease. For the "What's Trending" segment, Dr. Jeff Ratliff speaks with Dr. Lee Goldstein about teen concussion and early tauopathy.DISCLOSURES: Dr. Crowell reports no disclosures. Dr. Thompson has recieved research support from Novartis, NIH/NINDS (1U54 NS078059-06), NIEHS (P30 ES009089-15), and the FDA (UFDSP00011270). Dr. Hirano has received honoraria for serving on advisory boards of Stealth Biotherapeutics, Sarepeta, and Biogen; received received travel funds from the American College of Medical Genetics; has served as Nerve and Muscle editor of Current Neurology and Neuroscience Reports (2002-present); holds Rare Pediatric Disease (RPD) and Orphan Drug Designations (ODD) for deoxynucleoside therapy for mitochondrial DNA depletion syndrome including TK2 deficiency; received honoraria as a member of the Speakers' Bureau of Athena Diagnostics; and received research support from Santhera Pharmaceutical, Edison Pharmaceutical, National Institutes of Health (U54NS078059, R01HD056103 RC1NS070232 P01HD032062), Muscular Dystrophy Association (MDA) USA and Marriott Mitochondrial Disorder Clinical Research Fund (MMDCRF). Dr. Goldstein is a consultant for Rebiscan, Inc. Dr. Ratliff has received a speaker honorarium from Haverford College.

This special Delayed Recall episode is the third installment of our new Practice Current segment. In this episode, Dr. Luca Bartolini speaks with epilepsy experts Dr. Cynthia Harden and Dr. Torbjörn Tomson. They discuss the results of a recent Practice Current (a section of Neurology® Clinical Practice) survey regarding epilepsy treatment and management during pregnancy, and share their thoughts regarding best practices. This is the first appearance of this interview in the podcast.

1. Featured Article: IgLON5 antibody: Neurological Accompaniments & Outcomes in 20 patients2. What's Trending: Health policy update - Coding, Reimbursement & Quality Payment ProgramThis Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the March 27, 2018, print issue of Neurology. In the first segment, Dr. Stacey Clardy talks with Dr. Andrew McKeon about his Neurology: Neuroimmunology & Neuroinflammation paper describing IgLON5 autoimmunity. For the "What's Trending" segment, Dr. Jason Crowell speaks with Luana Ciccarelli and Amanda Napoles on regulatory updates in coding and reimbursement, MACRA, and tips for private practitioners on participating in the Quality Payment Program.DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR).Dr. McKeon has patent applications pending for GFAP and MAP1B as markers of neurological autoimmunity and paraneoplastic disorders; has consulted for Grifols, Medimmune, Inc., and Euroimmun (but did not receive personal compensation for these activities); and has received research support from Medimmune, Inc. and Euroimmun. Dr. Crowell reports no disclosures. Luana Ciccarelli and Amanda Napoles are employed by the American Academy of Neurology.

1. Featured Article: Molecular Genetic Testing for Hereditary Ataxia – What Every Neurologist Should Know2. What's Trending: Recent changes to Maintenance of Certification Requirements This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the March 20, 2018, print issue of Neurology. In the first segment, Dr. Jeff Ratliff talks with Dr. Thomas Bird about his Neurology: Clinical Practice paper on the benefits and limitations of exome sequencing to identify hereditary ataxias. For the "What's Trending" segment, Dr. Stacey Clardy with Dr. Laurie Gutmann about recent updates to the Maintenance of Certification requirements and tips to ease the process for neurologists.DISCLOSURES: Dr. Bird serves on the editorial board for GeneReviews.org; holds patents for genetic testing technology for CMT1C and SCA14; and has received research support from the Department of Veterans' Affairs (Merit Research Grant, PI, 2009-2017). Dr. Gutmann serves on the editorial board for Up-to-Date Online (Hypokalemic and Hyperkalemic Periodic Paralysis); and has recieved research support from Alexion Pharmaceuticals, Inc. and the NIH (U01 NS069498-01 A1, 3P50NS044283-07S1, U01 NS026835-01A1, U01 NS058728-01, and U01 NS077179-01). Dr. Ratliff has received a speaker honorarium from Haverford College. Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR).

1. Featured Article: Atrial fibrillation detected after stroke is related to a low risk of ischemic stroke recurrence2. What's Trending: Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnosesThis Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the first segment, Dr. Mark McAllister talks with Dr. Luciano Sposato about their paper on the relationship between atrial fibrillation detection and ischemic stroke recurrence. For the "What's Trending" segment, Dr. Ted Burns speaks with Dr. Mark Keegan and Dr. Nick Zalewski about their paper on idiopathic transverse myelitis and myelopathy diagnoses.DISCLOSURES: Dr. Sposato has received travel or speaker honoraria from Boehringer Ingelheim and Pfizer; serves on the Editorial Board for Neurology; and has received research support from Kathleen & Dr Henry Barnett Research Chair in Stroke Research, Boehringer Ingelheim (salary support for a fellow), Edward and Alma Saraydar Neurosciences Fund, Opportunities Fund of the Academic Health Sciences Centre Alternative Funding Plan of the Academic Medical Organization of Southwestern Ontario, and Boehringer Ingelheim. Dr. Keegan serves on the editorial board for Multiple Sclerosis and Related Disorders; receives publishing royalties for Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases: Case-Based Learning (Cambridge University Press, 2016); has consulted for Novartis, Bristol Meyers Squibb, and Bionest; and has received research support from Biogen (ARISE study). Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring. Dr. McAllister and Dr. Zalewski report no disclosures.

This month's Delayed Recall episode includes three recent interviews on the topic of cognitive impairment. In the first interview, from the January 16, 2018 episode, Dr. Jeff Burns speaks with Dr. Ronald Petersen about the recent AAN practice guideline paper on mild cognitive impairment. Next, in and interview from the January 2, 2018 podcast, Dr. Ted Burns and Dr. Damian Garde discuss recent Alzheimer disease trials; and in the third and final interview, Dr. Matthew Elliot talks with Dr. Hugh Markus about his paper "Multimodal MRI markers and dementia risk in cerebral small vessel disease." This interview first aired in the October 31, 2017 episode of the podcast.

1. Featured Article: Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era2. What's Trending: Sleep architecture and risk of dementiaThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the March 6, 2018, issue of Neurology. In the first segment, Dr. Stacey Clardy talks with Dr. Raed Alroughani about his article on relapse recurrence during pregnancy in women with multiple sclerosis. In the second part of the podcast, you'll hear Dr. Jeff Burns interviews Dr. Sudha Seshadri about sleep and dementia risk.DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Alroughani served in scientific advisory boards of Novartis, Bayer, Merck-Sorono, Roche, Biogen, Sanofi-Geznyme; has received speaker and travel honoraria from Novartis, Bayer, Merck-Sorono, Biogen, Roche, Sanofi-Genzyme and GSK; and has received research grants from Biogen, Novartis and Sanofi-Genzyme.Dr. Burns has served on the DSMB for NIH-funded trials (non-profit entities); serves on the editorial board for Journal of Alzheimer's Disease; has consulted for Grifols, USA; has served on Eli Lilly Amyvid Speaker's Bureau; and has received research support from Eli Lilly, Avid Radiopharmaceuticals, Toyama Chemical Company, Merck, Biogen, AbbVie, Novartis, vTv Therapeutics, Janssen, and NIH (R01AG058557, R01AG053312, R01AG034614, R01AG03367, R01AG043962, P30AG035982, U10NS077356, UL1TR000001).Dr. Seshadri serves on editorial boards for Journal of Alzheimer's Disease, Stroke, and Neurology; and has received research support from NIA (AG008122, AG033040, AG049505, AG033193, AG049607, AG054076).

1. Featured Article: Interdisciplinary Response to Contemporary Concerns about Brain Death Determination2. What's Trending: Gene Drive, part 2This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the February 27, 2018 issue of Neurology. In the first segment, Dr. Andy Schomer talks with Dr. Ariane Lewis about her paper on the determination of brain death. In the second part of the podcast, Dr. Ted Burns speaks with Dr. Kevin Esvelt for part two of the discussion on gene drives (the first of these segments aired in the Feb. 20 episode).

1. Featured Article: Intravenous thrombolysis and platelet count2. What's Trending: Gene Drives, part IThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the February 6, 2018, issue of Neurology. In the first segment, Dr. Kevin Barrett talks with Dr. Henrik Gensicke about his article on the effect of platelet count on bleeding risk and mortality in stroke patients treated with IV thrombolysis. In the second part of the podcast, you'll hear the first part of Dr. Ted Burns' interview with Dr. Kevin Esvelt about gene drives.DISCLOSURES: Dr. Barrett serves on the editorial board of Neurology and Neurohospitalist; has received research/grant support from the National Institute of Neurological Disorders and Stroke for serving on the executive committees of the CREST-2 and SHINE clinical trials; and receives publishing royalties from Wiley Blackwell. Dr. Gensicke receives research support from Swiss National Science Foundation (33CM30-124119 and P300PB_161071). Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring. Dr. Esvelt reports no disclosures.

1. Featured Article: Medical Retirement from Sport after Concussions: a practical guide for a difficult discussion2. What's Trending: CGRP drugs and treatment of migraineThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the February 13, 2018 issue of Neurology. In the first segment, Dr. Jason Crowell talks with Dr. James Noble about his Neurology® Clinical Practice paper on athletes who retire from sport following concussion. In the second part of the podcast, Dr. Tesha Monteith focuses her interview with Dr. Peter Goadsby on CGRP and migraine. DISCLOSURES: Dr. Crowell reports no disclosures. Dr. Noble received travel honoraria for the Big 10/Ivy League concussion summit; has a pending patent for a real-time concussion diagnostic tool; has consulted with Prophase, LLC; has received research support from NIH (U54 NS081765, R01 NS067443, R01AG054536, T35 AG044303); and holds stock options in BATS-TOI. Dr. Goadsby has consulted for Akita, Allergan, Amgen, Autonomic Technologies Inc, Avanir, Cipla, Dr Reddy's Laboratories, Eli-Lilly, Electrocore, eNeura, Pfizer, Scion, Teva, and Trigemina; serves on editorial boards for NEJM Journal Watch, and Neurology Up-to-Date; receives publishing royalties for Mechanism and Management of Headache (Elsevier 2005); holds stock options in Trigemina Inc.; and receives research support from Amgen, and Eli-Lilly. Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH.

Featured Article: Burnout, Wellness, and the Future of Our ProfessionThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the February 6, 2018, issue of Neurology. This week, Dr. Ted Burns talks with Dr. Terry Cascino about his special address on burnout and the future of neurology. DISCLOSURES: Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring. Dr. Cascino is the immediate past president of the American Academy of Neurology.

This month's Delayed Recall episode comprises an update regarding recent developments in the field of stroke, and includes four interviews from 2017 that focused on this topic. The first interview aired in the September 12 episode, and features a discussion between Dr. Kevin Barrett and Dr. Tudor Jovin regarding the recent DAWN trial. Next, Dr. David Ackerman and Dr. Gene Latorre take a look at the stroke rehabilitation quality measurement set update that was published in Neurology® in October of 2017. This interview appeared as part of the Oct. 10 podcast episode. The third interview of this month's Delayed Recall was featured in the October 24 episode; in it, Dr. Justin Sattin talks about the use of Tenecteplase for acute ischemic stroke with Dr. Nicola Logallo. The final interview, by Dr. Nichole Chiota with Dr. Steven Messe, covers the recent PFO Update. This segment was featured in the November 7 episode.

1. Featured Article: Racial disparities in refusal of stroke thrombolysis in Chicago2. Lesson of the Week: Emergency management of migraineThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 30, 2018, issue of Neurology. In the first segment, Dr. Jennifer Majersik talks with Dr. Scott Mendelson about his paper on differences in tPA refusal in black vs non-black patients with acute ischemic stroke. In the second part of the podcast, Dr. Teshamae Monteith focuses her Lesson of the Week interview with Dr. Benjamin Friedman on IV prochlorperazine plus diphenhydramine vs IV hydromorphone for emergency migraine treatment.DISCLOSURES: Dr. Majersik serves on the editorial board for Neurology; receives research support from National Institutes of Health (grant U10 NS086606); and served as an expert witness for FAVROS, LCC. Dr. Mendelson has received travel honoraria from Medtronic; has received research support from University of Chicago and Institute of Medicine of Chicago. Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH. Dr. Friedman reports no disclosures.

1) Featured Article: Collateral response modulates the time–penumbra relationship in proximal arterial occlusions2) Lesson of the Week: Migraine and neuromodulationThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 23, 2018, issue of Neurology. In the first segment, Dr. Kevin Barrett talks with Dr. Smriti Agarwal about her paper on collateral circulation in proximal arterial occlusions and extending the scope of thrombolytic therapy. In the second part of the podcast, Dr. Teshamae Monteith focuses her Lesson of the Week interview with Dr. Stewart Tepper on acute and preventative neuromodulation treatment for migraine. DISCLOSURES: Dr. Barrett serves on the editorial board of Neurology and Neurohospitalist; has received research/grant support from the National Institute of Neurological Disorders and Stroke for serving on the executive committees of the CREST-2 and SHINE clinical trials; and receives publishing royalties from Wiley Blackwell.Dr. Agarwal reports no disclosures.Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH.Dr. Tepper is a member of the board for the American Headache Society and has been a consultant for or participated on a paid advisory board for Acorda Therapeutics, Inc; Alder BioPharmaceuticals, Inc; Allergan plc; Amgen, Inc; Avanir Pharmaceuticals, Inc; BioVision, Inc; Charleston Laboratories, Inc; Dr. Reddy's Laboratories, Ltd; electroCore, LLC; eNeura, Inc; Eli Lilly and Company; GLG Pharma, LLC; Guidepoint Inc, LLC, Ltd; Kimberly-Clark Corporation; Pernix Therapeutics Holdings, Inc; Pfizer, Inc; Scion NeuroStim, LLC; Teva Pharmaceutical Industries, Ltd; and Zosano Pharma, Corp.

1. Featured Article: Practice guideline update summary: Mild cognitive impairment2. Lesson of the Week: Migraine and hormonesThis Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 16, 2018, print issue of Neurology. In the first segment, Dr. Jeff Burns talks with Dr. Ronald Petersen about the updated 2001 AAN guideline on prevalence, prognosis, and treatment of MCI. For the Lesson of the Week, Dr. Teshamae Monteith speaks with Dr. Jelena Pavlovic about the association between hormones and migraine. DISCLOSURES: Dr. Burns has served on the DSMB for NIH-funded trials (non-profit entities); serves on the editorial board for Journal of Alzheimer's Disease; has consulted for Grifols, USA; has served on Eli Lilly Amyvid Speaker's Bureau; and has received research support from Eli Lilly, Avid Radiopharmaceuticals, Toyama Chemical Company, Merck, Biogen, AbbVie, Novartis, vTv Therapeutics, Janssen, and NIH (R01AG058557, R01AG053312, R01AG034614, R01AG03367, R01AG043962, P30AG035982, U10NS077356, UL1TR000001).Dr. Petersen receives publishing royalties from Mild Cognitive Impairment (Oxford University Press, 2003); has consulted for Roche Incorporated, Merck, Genentech, and Biogen; and receives research support from National Institute on Aging (U01-AG006786, P50-AG016574, U01-AG024904, and U01-AG016976). Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH.Dr. Pavlovic has received consulting honoraria and travel support from Allergan, Inc. and travel/conference registration support from The American Headache Society.

1) Featured Article: Quality improvement in neurology: Child neurology quality measure set2) Lesson of the Week: Update on chronic migraine risk factors, management, and treatmentThis Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 9, 2018, issue of Neurology. In the first segment, Dr. Adam Numis talks with Dr. Jeffrey Buchhalter and Dr. Anup Patel about their quality measure set executive summary article regarding child neurology. For the "Lesson of the Week" segment, Dr. Tesha Monteith speaks with Dr. Stephen Silberstein about chronic migraine.DISCLOSURES:Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section; has received speaker honorarium from LivaNova; and has received research support from American Academy of Neurology, Clinical Research Training Fellowship in Epilepsy, 2017-2019, and American Epilepsy Society, Research and Training Fellowships for Clinicians, 2017-2018.Dr. Bucchalter has served on advisory and safety monitoring boards for NIH, NINDS, Observational Safety Monitoring Board for NIH, and the Charlie Foundation; has received travel and speaker honoraria from AAN, Eisai Co. Ltd., Child Neurology Society, Lundbeck, and Upsher-Smith Labs; serves on the editorial board for Pediatric Neurology; has consulted in the past with Lundbeck Inc., Eisai Co. Ltd., UCB, and Upsher-Smith; and has received research support from Alberta Health Services.Dr. Patel has served on scientific advisory board for UCB Pharma; has served as book and associate editor for Journal of Child Neurology; has consulted for Greenwich Biosciences, LivaNova, and Supernus; and has received research support from Greenwich Biosciences, Brain Sentinel, Upsher Smith Pharmaceuticals, LivaNova, Pediatric Epilepsy Research Foundation (PERF), and American Academy of Neurology (AAN).Dr. Silberstein has served on scientific advisory boards for Alder, Allergan, Amgen, Avanir, eNeura, ElectroCore Medical, Medscape, Medtronic, Mitsubishi Tanabe, Neuralieve, NINDS, Pfizer, Supernus, Teva, Curelator, Depomed, Dr. Reddy's Laboratories, Lilly, and Trigemina; has served on editorial boards for Cephalalgia, Current Pain and Headache Reports, CNS Drugs, Topics in Pain Management, and Neurology; has consulted for Allergan, Amgen, eNeura, ElectroCore Medical, Mitsubishi Tanabe, Medtronic, Neuralieve, Pfizer, Supernus, and Teva; served on speaker's bureaus in the past for Allergan, Endo Pharmaceuticals, GlaxoSmithKline, Zogenix, and Merck; and has received research support from GlaxoSmithKline, Allergan, Merck, Novartis, NIH, Neurolieve, MAP, Endo, Amgen, ElectroCore, Avanir, NIH, AHS, and IHS.Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH.

1) Featured Article: Clinical biomarkers differentiate myelitis from vascular and other causes of myelopathy 2) What's Trending: Clinical Trials in Alzheimer Disease This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the first segment, Dr. Stacey Clardy talks with Dr. Carlos Pardo about his paper on clinical biomarkers and differential diagnosis of myelitis. For the "What's Trending" segment, Dr. Ted Burns speaks with journalist Damian Garde about the recent Clinical Trials in Alzheimer Disease conference. DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Pardo has served on scientific advisory board for the Transverse Myelitis Association; has received research support from Accorda Pharmaceuticals, Chugai Pharmaceutical Co. LTD, Medimmune, NIH/NINDS (R21NS076381, R01NS055628, R21TW0009741, P30MH075673, 1R01HL130649-01), and the Bart McLean Neuroimmunology Fund from the Transverse Myelitis Association. Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring. Mr. Garde reports no disclosures.

Patient Perspectives, Part II (January 2018)This month's Delayed Recall episode is the second part of our feature including interviews that focus on the patient perspective. The first part of this feature aired as the Delayed Recall episode for December 2017. We feature four interviews in this second installment; the first is Dr. Alberto Espay's interview with Dr. Ted Burns in the Sept. 3, 2013 episode, in which they discuss Dr. Burns' cancer diagnosis and his subsequent experience as a patient. In the second interview, with Dr. Lara Marcuse, Dr. Marcuse responds to Dr. Espay's Sept. 2013 interview with Dr. Burns, and remarks briefly on her own time as a patient. This interview was part of the October 29, 2013 episode. The third interview features Dr. Espay and Dr. Burns once more; they discuss Dr. Burns' cancer recurrence, as well as Dr. Burns' view about the kind of care that he believes is important for healthcare providers to focus on. This interview first appeared in the August 1, 2017 episode. Last, we feature an interview from the June 3, 2008 episode, between Dr. Ted Burns and Dr. Bob Joynt, in which Dr. Joynt offers his advice regarding patient treatment.

1) Neurology: Neuroimmunology & Neuroinflammation: Cryptogenic NORSE: Its distinctive clinical features and response to immunotherapy 2) What's Trending: R&F section update with Dr. Roy StrowdThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the December 12, 2017 issue of Neurology. In the first segment, Dr. Stacey Clardy talks with Dr. Takahiro Iizuka about his paper on diagnosis and treatment of new-onset refractory status epilepticus (NORSE). In the second part of the podcast, Dr. Jeff Ratliff focuses his interview with Dr. Roy Strowd on a highlighted Clinical Reasoning case from the new "Resident & Fellow Rounds" feature debuting in 2018.DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Langer-Gould has received research support from Biogen, Roche, NIH, PCORI, and the National Multiple Sclerosis Society. Dr. Iizuka serves on editorial boards for Current Treatment Options in Neurology and Rinsho Shinkeigaku (Clinical Neurology), and has received research support from Mitsubishi Tanabe Pharma Corporation (MTPS20160504012) and the Japan Epilepsy Research Foundation (JERFTENKAN 17002).Dr. Ratliff has received a speaker honorarium from Haverford College. Dr. Strowd serves on the editorial board of Neurology (Resident & Fellow section); and has received research support from the Wake Forest School of Medicine Center for Translational Sciences Award, the KL2 Career Development Award, and the American Academy of Neurology.

Show description/summary:1) Long-term benefit of enzyme-replacement therapy in Pompe disease: A 5-year prospective study2) What's Trending: ACTH or prednisolone for infantile ataxiaThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the December 5, 2017 issue of Neurology. In the first segment, Dr. Kelly Gwathmey talks with Dr. Nadine van der Beek about her paper on enzyme-replacement therapy in Pompe disease. In the second part of the podcast, Dr. Ted Burns focuses his interview with Dr. John Mytinger on the topic of ACTH or prednisolone for infantile ataxia. DISCLOSURES: Dr. Gwathmey reports no disclosures.Dr. van der Beek has received speaker honoraria from Sanofi-Genzyme (paid to to Erasmus MC for further research purposes); and has received research support from Sanofi-Genzyme, Colciencias, ZonMW - the Netherlands Organization for Health Research and Development, the Prinses Beatrix Spierfonds, SSWO – Sophia Children's Hospital Foundation, and TKI-Health Holland.Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring.Dr. Mytinger reports no disclosures.

This month's Delayed Recall episode is the first in a duo of episodes featuring interviews that focus on the patient perspective. The second part of this feature will appear as the Delayed Recall episode for January 2018. As the first of the three interviews included in December's episode, we feature an interview by Dr. Ted Burns with Dr. Oliver Sacks regarding Dr. Sacks' experience with ocular melanoma. This interview originally aired in January 2011, and appeared again as part of a Delayed Recall episode in 2015, which was aired as a tribute to Dr. Sacks following his passing. In the second interview of this episode, from February 19, 2013, Dr. Burns speaks with Dr. Bob Holloway on communicating prognosis for patients with serious neurological diseases. In the third and final interview in this episode, Dr. Burns speaks with Dr. Richard Morton about his essay regarding his experience as a patient. This interview was part of the July 25, 2017 podcast episode.

1) Midlife systemic inflammatory markers are associated with late-life brain volume: The ARIC study2) What's Trending: Neurology paper on breast feeding, ovulatory years, and risk of multiple sclerosisThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the November 28, 2017 issue of Neurology In the first segment, Dr. Jeff Burns talks with Dr. Keenan Walker about his paper on the association between systemic inflammation and brain volume over time. For our What's Trending segment, Dr. Stacey Clardy focuses her interview with Dr. Annette Langer-Gould about her recent Neurology article on breast feeding, ovulatory years, and risk of multiple sclerosis.DISCLOSURES: Dr. Burns has served on the DSMB for NIH-funded trials (non-profit entities); serves on the editorial board for Journal of Alzheimer's Disease; has consulted for Grifols, USA; has served on Eli Lilly Amyvid Speaker's Bureau; and has received research support from Eli Lilly, Avid Radiopharmaceuticals, Toyama Chemical Company, Merck, Biogen, AbbVie, Novartis, vTv Therapeutics, Janssen, and NIH (R01AG058557, R01AG053312, R01AG034614, R01AG03367, R01AG043962, P30AG035982, U10NS077356, UL1TR000001)Dr. Walker has received research support from the National Institute of Aging (AG027668, postdoc fellow, 2016-17).Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR).Dr. Langer-Gould has received research support from Biogen, Roche, NIH, PCORI, and the National Multiple Sclerosis Society.

Show description/summary:1) Multiparametric MRI changes persist beyond recovery in concussed adolescent hockey players 2) Neurology Today® paper on the increase in gabapentinoid prescriptionThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the November 21, 2017 issue of Neurology. In the first segment, Dr. Ted Burns talks with Dr. Kathryn Manning and Dr. Ravi Menon about their paper regarding the effects of concussion on adolescent hockey players. In the second part of the podcast, Dr. Burns focuses his interview with Dr. Christopher Goodman about a recent Neurology Today article discussing the increase in gabapentinoid prescriptions. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring.Dr. Manning reports no disclosures.Dr. Menon has served on the scientific advisory board of International Initiative for Traumatic Brain Injury Research (NIH/EU/CIHR); has served on the editorial boards of NeuroImage, Journal of Neurophysiology, Scientific Reports, and Tomography; has received research support from Siemens Healthineers, Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, Canada First Research Excellence Fund, and Brain Canada Foundation; and has received royalty payments from Siemens Healthcare for US Patent 8,193,812.Dr. Goodman reports no disclosures.

Show description/summary:1) Infliximab for the treatment of central nervous system sarcoidosis: A multi-institutional series2) What's Trending: Sonic traumatic brain injuryThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the November 14, 2017 issue of Neurology. In the first segment, Dr. Stacey Clardy talks with Dr. Siddharama Pawate and Dr. Jeff Gelfand about their paper on infliximab for treatment of central nervous system sarcoidosis. In the second part of the podcast, Dr. Alex Menze focuses his interview with Dr. Jeffrey Kim on the recent speculation around sonic traumatic brain injury.DISCLOSURES: Dr. Gelfand has served on scientific advisory boards for Genentech; has received compensation for consulting with Genentech; has received research support from Quest Diagnostics, Genentech, MedDay, and NIH National Center for Advancing Translational Sciences (KL2TR000143); and has received compensation for serving as expert witness in medical-legal consulting. Dr. Pawate has served on scientific advisory board for Biogen, and has received research support from Biogen.Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR).All other participants report no disclosures.

Show description/summary:1) This variant alters protein function, but is it pathogenic? (Neurology® Genetics)2) What's Trending: PFO UpdatesThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the November 7, 2017 issue of Neurology. In the first segment, Dr. Michelle Mauermann talks with Dr. Massimo Pandolfo about his recent Neurology® Genetics editorial, entitled "This variant alters protein function, but is it pathogenic?". In the second part of the podcast, Dr. Nicole Chiota focuses her interview with Dr. Steven Messe on recent PFO/stroke updates. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Mauermann serves on the editorial board of Mayo Clinic Proceedings; receives publishing royalties from Oxford, and has received research support from Ionis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals.Dr. Pandolfo has served on the scientific advisory boards of Apopharma and Voyager Therapeutics; has served on the editorial boards of Acta Neurologica Belgica, Orphanet Journal of Rare Diseases, and Neurology Genetics; is co-holder of a patent for Direct molecular diagnosis of Friedreich's ataxia; has been a consultant for Biomarin and UCB; has received research support from Biomarin, Fonds National de la Recherche Scientifique (Belgium), Offrez-moi-la-lune, Friedreich's Ataxia Research Alliance, and Association Belge contre les Maladies neuro-Musculaires, and receives royalty payments from Athena Diagnositcs for a Friedreich's ataxia diagnostic test.Dr. Chiota reports no disclosures.Dr. Messe has served on the scientific advisory board of the Yale University Cardiovascular Research Group; has received travel funding from the American Academy of Neurology; has received publishing royalties from Up To Date; has been a consultant for Claret Medical; and has received research support from WL Gore, Glaxo Smith Kline, Bayer, Mallinkrodt, and NIH.

This month's Delayed Recall episode features Dr. Stacey Clardy's Lesson of the Week interviews on the topic of immunotherapy, which originally aired in July 2017. In the first interview, Dr. Clardy speaks with Dr. Dennis Bourdette about new immunotherapies in neurology. This interview first appeared in the July 4 episode. In the interview from July 11, Dr. Clardy continues the discussion about new immunotherapies with Dr. Jeffrey Cohen. The third interview, from the July 18 episode, features Dr. Clardy speaking with Dr. Emmanuelle Waubant about immunotherapy as it applies to multiple sclerosis patients. To conclude this episode, we offer Dr. Clardy's interview with Dr. Anne Cross, in which they talk about immunosuppressants in Neurology; this interview was part of the July 25 episode.

Show description/summary:1) Change in multimodal MRI markers predicts dementia risk in cerebral small vessel disease2) What's Trending: dabigatran reversal in patients with uncontrolled bleeding This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the October 31, 2017, issue of Neurology. In the first segment, Dr. Matthew Elliot talks with Dr. Hugh Markus about his paper multimodal MRI markers and dementia risk in cerebral small vessel disease. In the second part of the podcast, Dr. Bryan Eckerle focuses his interview with Dr. Charles Pollack on dabigatran reversal in patients with uncontrolled bleeding or receiving surgery. DISCLOSURES: Dr. Markus serves as section editor of International Journal of Stroke; serves on the editorial board for Clinical Neurology and Neurosurgery, and BMC Medicine; serves as Associate Editor for Fronteirs in Neurology; receives publishing royalties from Stroke Medicine (OUP 2016); has consulted and led a teaching session for Astra Zeneca; and has received research support from MRC, NIHR, Stroke Association, EU, Wellcome Trust, The British Heart Foundation, and Alzheimer Research UK. Dr. Eckerle and Dr. Elliot report no disclosures.Dr. Pollack has received research support from Boehringer Ingelheim, Daiichi Sankyo, CSL Behring, Janssen Pharma, AstraZeneca, and Portola; and has served as scientific consultant for Boehringer Ingelheim, BMS/Pfizer, Janssen Pharma, AstraZeneca, and Portola.

Show description/summary:1) Persistent focal enhancement of the cisternal segment of oculomotor nerve in ophthalmoplegic migraine (Neurology® Clinical Practice)2) What's Trending: Tenecteplase for acute ischemic strokeThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the October 24, 2017 issue of Neurology. In the first segment, Dr. Heather Harle talks with Dr. Ihtesham Qureshi about his Neurology® Clinical Practice paper on ophthalmoplegic migraine. In the second part of the podcast, Dr. Justin Sattin focuses his interview with Dr. Nicola Logalio on using tenecteplase for acute ischemic stroke. Disclosures can be found at Neurology.org.DISCLOSURES: All participants report no disclosures.

Show description/summary:1) Qualitative study of burnout, career satisfaction, and well-being among US neurologists in 20162) What's Trending: gene editing in human embryosThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the October 17, 2017, issue of Neurology. In the first segment, Dr. Pearce Korb talks with Dr. Janis Miyasaki about her paper on burnout, career satisfaction and well-being among US neurologists. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Shoukhrat Mitalipov on gene editing in human embryos for correction of a pathogenic mutation.DISCLOSURES: Dr. Miyasaki has received honoraria from Davis Phinny Foundation, Sunovion, and NINDS; receives publishing royalties from "Up to Date: Psychogenic Movement Disorders;" has consulted for Cynapsus and GE; has served on a scientific advisory board for Parkinson Society Canada; and has received research support from Allergan, PCORI, and Parkinson Alberta.Dr. Mitalipov holds patents for Primate Totipotent and Pluripotent Stem Cells Produced by Somatic Cell Nuclear Transfer (U.S. patent No. 7,972,849), Human Pluripotent Stem Cells Produced by Somatic Cell Nuclear Transfer (U.S. Patent No. 9,546,383), and Methods for Mitochondrial DNA Replacement in Oocytes (U.S. Patent No. 9434921); has patents pending for Metabolic rescue in pluripotent cells from subjects with mitochondrial DNA disease (Application Number: 62192358), Generation of human oocytes by polar body transfer" (Application 62/419,638), and Mitochondrial Replacement in Human Oocytes Carrying Pathogenic Mitochondrial DNA Mutations (Application 62427546); has consulted for Flagship VentureLabs; and has received research support from NIH/NIA, Burroughs Wellcome Fund, and Foundation Leducq.Dr. Korb and Dr. Crowell report no disclosures.

Show description/summary:1) Quality improvement in neurology: Stroke and stroke rehabilitation quality measurement set update2) Neurology Today® paper on Parkinson disease and autoimmunityIn the first segment, Dr. Dan Ackerman talks with Dr. Gene Latorre about his paper on the updated quality measurement set for stroke and stroke rehabilitation. In the second part of the podcast, Dr. Alberto Espay focuses his interview with Dr. David Sulzer on Parkinson disease and autoimmunity. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.All other participants report no disclosures.

Show description/summary:1) Functional impairments for outcomes in a randomized trial of of unruptured brain AVMs2) What's Trending: Hurricane Harvey and patient care in TexasThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the October 3, 2017, issue of Neurology. In the first segment, Dr. Andrew Southerland talks with Dr. JP Mohr about his paper on functional impairment outcome measurements in a randomized trial of unruptured brain arteriovenous malformations. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Aziz Shaibani on Hurricane Harvey and its effect on patient care in Texas. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Southerland serves as Podcast Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: "Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;" and gave legal expert review.Dr. Mohr serves as Associate Editor for History of Stroke and Cerebrovascular Disease; has consulted for Schering-Plough; has given expert testimony on unruptured brain AVMs; and has received research support from NINDS associated with the ARUBA trial. Dr. Crowell reports no disclosures.Dr. Shaibani is President-Elect for the Texas Neurology Society.

This special Delayed Recall episode is the second installment of our new Practice Current segment. In this episode, Dr. Luca Bartolini speaks with neuromyelitis optica (NMO) experts Dr. Tarso Adoni and Dr. Michael Levy. They discuss the results of a recent Practice Current (a section of Neurology® Clinical Practice) survey regarding NMO treatment, and share their thoughts on best practices. This is the first appearance of this interview in the podcast.

Show description/summary:1) Neurology® Genetics: ExACtly zero or once: A clinically helpful guide to assessing genetic variants in mild epilepsies 2) What's Trending: Orphan drug pricingThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the September 26, 2017 issue of Neurology. In the first segment, Dr. Jim Kiely talks with Dr. Samuel Berkovic about his Neurology® Genetics paper on assessing genetic variants in mild epilepsies. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Gordon Smith on orphan drug pricing. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Kiely is employed at InTouch Health Physician Services as a teleneurologist, and holds stock with InTouch Health. Dr. Berkovic serves on scientific advisory board for UCB Pharma and Eisai Australia; has served on editorial boards for Brain, Epileptic Disorders, and Lancet Neurology; is an investor listed on a Bionomics Inc patent on diagnostic testing using SCN1A gene (WO2006/133508), and is an investor on a pending patent for a therapeutic compound related to a genetic cause of familial epilepsy with mental retardation in females (WO61/010176); receives research support from UCB, SciGen, and Eisai Australia, the National Health and Medical Research Council of Australia (Program Grant #1091593; 2016-2020), and NINDS (U01 NS077367-01; 2011-2014).Dr. Smith serves on the Celegene data monitoring committee; serves as editor for NeuroLearn; has consulted for Regenesis, Allergan, and Viromed; and receives research support from Impeto Medical, and NIDDK (DK064814), NINDS (U10NS077305 and U10NS086606).Dr. Crowell reports no disclosures.

Show description/summary:1) Medication-overuse headache: An entrenched idea in need of scrutiny 2) What's Trending: DAWN TrialThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the September 19th, 2017 issue of Neurology. In the first segment, Dr. Alex Menze talks with Dr. Elizabeth Loder about her paper on medication overuse headache. In the second part of the podcast, Dr. Kevin Barrett focuses his interview with Dr. Tudor Jovin on the DAWN trial on Trevo thrombectomy for acute ischemic stroke. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Menze reports no disclosures.Dr. Loder has received travel funding from the American Headache Society and American Migraine Foundation and The British Medical Journal; has served on the editorial boards of The British Medical Journal, Cephalalgia, and Headache; receives publishing royalties from Cambridge University Press; and has received research support from Harvard Medical School.Dr. Barrett serves on the editorial boards of Neurology and Neurohospitalist; receives publishing royalties from Wiley-Blackwell; and has received research support from NINDS.Dr. Jovin has served on the Codman Neurovascular Data Safety Monitoring Board; has received travel funding from Stryker Neurovascular and Fundacio Ictus; and holds stock/stock options in Silk Road Medical, Anaconda, and Blockade Medical.

Show description/summary:1) National randomized controlled trial of virtual house calls for Parkinson disease2) Neurology Today: Interview with Joseph Safdieh, the new Editor-in-Chief of Neurology Today®This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the September 12, 2017 issue of Neurology. In the first segment, Dr. Jeff Ratliff talks with Dr. Ray Dorsey about his paper on virtual house calls for Parkinson disease. In the second part of the podcast, Dr. Andy Southerland interviews Dr. Joseph Safdieh about Dr. Safdieh's new position as Editor in Chief of Neurology Today. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Ratliff has received a speaker honorarium from Haverford College.Dr. Dorsey has served on the scientific advisory boards of Shire Pharmaceuticals and Huntington's Disease Society of America; has received travel funding and/or honoraria from the American Academy of Neurology and the American Neurological Association; has served on the editorial boards of the Journal of Huntington's Disease, HD Insights, and Digital Biomarkers; has been a consultant for 23andMe, Abbott Nutrition, Abbvie, Amgen, Biogen, Clintrex, GlaxoSmithKline, Grand Rounds, Lundbeck MC10, MedAvante, Medico Legal services, NIH/NINDS Optio, Shire, Sunovion Pharma, Teva, UCB, Voyager Therapeutics, State of Georgia, Mednick Associates, and Putnam Associates; has performed clinical practice, including telemedicine, as a movement disorder neurologist; has received research support from Abbvie, AMC Health, Avid Radiopharmaceuticals, BioMarin, GlaxoSmithKline, Great Lakes Neurotechnologies, Lundbeck, Medtronic, Prana Biotechnology, Raptor Pharmaceuticals, Roche, Teva Pharmaceuticals, National Institute of Neurological Disorders and Stroke, Patient-Centered Outcomes Research Institute, University of California Irvine, Duke University, Burroughs Wellcome Fund, Davis Phinney Foundation, Michael J. Fox Foundation, Safra Foundation, Greater Rochester Health Foundation, Huntington Study Group, and National Science Foundation; holds Grand Rounds and BlackFlynn stock options; and has received compensation for expert testimony.Dr. Southerland serves as Podcast Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: "Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;" and gave legal expert review.Dr. Safdieh has served on the scientific advisory board for Upsher Smith; is the Editor-in-Chief of Neurology Today, has received publishing royalties from Elsevier, and has performed consultant work regarding legal proceedings.

Show description/summary:1) Longitudinal diffusion changes following postoperative delirium in older people without dementia2) What's Trending: Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adultsThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the September 5, 2017 issue of Neurology. In the first segment, Dr. Pearce Korb talks with Dr. Michele Cavallari and Dr. David Alsop about their paper on longitudinal diffusion changes following postoperative delirium in people without dementia. In the second part of the podcast, Dr. Jeff Burns focuses his interview with Dr. Barbara Bendlin on poor sleep and biomarkers of amyloid pathology in cognitively normal adults. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Alsop serves as associate editor for Magnetic Resonance in Medicine; has received research support from GE Healthcare Technologies, NIH (P01 AG031720, R01 MH080729, R01 NS047029, R21 EB014471, R01 CA169470, P20 DK108276, R44 DK111260); and receives royalty payments for Patent 7,545,142 (arterial spin labeling with pulsed radio frequency sequences) and from GE Healthcare, Philips Healthcare, Siemens Medical, Hitachi Medical, and Animage Technology.Dr. Cavallari has received research support from NIA (P01AG03172).Dr. Burns has served on the DSMB for NIH-funded trials (non-profit entities); serves on the editorial board for Journal of Alzheimer's Disease; has consulted for Grifols, USA; has served on Eli Lilly Amyvid Speaker's Bureau; and has received research support from Eli Lilly, Avid Radiopharmaceuticals, Toyama Chemical Company, Merck, Biogen, AbbVie, Novartis, vTv Therapeutics, Janssen, and NIH (R01AG058557, R01AG053312, R01AG034614, R01AG03367, R01AG043962, P30AG035982, U10NS077356, UL1TR000001). Dr. Bendlin serves as associate editor for Journal of Alzheimer's Disease; and has received research support from NIH/NIA (Alzheimer's Disease Connectome Project, U01AG051216, P50 AG033514, R01AG037639, R56AG052698, R21AG053738, P50 AG033514, 1U54AI117924).Dr. Korb reports no disclosures.

The first interview in this month's Delayed Recall episode is from March 17, 2015; in this interview, Dr. Howard Goodkin and Dr. Robert Stern discuss the effect that age of first exposure to football has on later-life cognitive impairment in former NFL players. The second interview, from August 29, 2017, is a discussion between Dr. Jason Crowell and Dr. Jesse Mez about a July 2017 JAMA paper on occurrence of CTE in American football players. In the third interview, Dr. Christopher Giza speaks with Dr. John Hart about Dr. Hart's paper regarding depressive symptoms and white matter dysfunction in retired NFL players with concussion history. This interview originally appeared in the July 1, 2013 episode. The fourth and final interview is a discussion between Dr. Ted Burns and former NFL player Ben Utecht, regarding Mr. Utecht's Sept 23, 2014 editorial, "Concussed."

Show description/summary:1) Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome2) What's Trending: CTE and American football playersThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the August 29, 2017 issue of Neurology. In the first segment, Dr. Nicholas Brenton talks with Dr. Kevin Rostásy about his paper on the prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Jesse Mez on chronic traumatic encephalopathy and American football players. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Rostásy serves on a scientific advisory board for Novartis regarding a fingolimod project, and has received speaker honoraria for Merck-Serono.Dr. Smith serves on the Celegene data monitoring committee; serves as editor for NeuroLearn; has consulted for Regenesis, Allergan, and Viromed; and receives research support from Impeto Medical, and NIDDK (DK064814), NINDS (U10NS077305 and U10NS086606).All other participants report no disclosures.

Show description/summary:1) Oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome2) Neurology Today: FDA Approves Edaravone for ALS: Phase 3 Trial Finds It Slows ProgressionThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the August 22, 2017 issue of Neurology. In the first segment, Dr. Halley Alexander talks with Mr. Mohit Sodhi about his paper on oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome. In the second part of the podcast, Dr. Kelly Gwathmey focuses her interview with Dr. Terry Heiman-Patterson on a Neurology Today® story about the FDA-approval of edaravone for the treatment of ALS. Disclosures can be found at Neurology.org.DISCLOSURES: All participants report no disclosures.

Show description/summary:1) Quality improvement in neurology: Inpatient and emergency care quality measure set executive summary 2) Neurology Today: Incidental findings and normal variants on MRI of the brain in adults for primary headachesIn the first segment, Dr. Jason Crowell talks with Dr. Paul Vespa about his paper on quality improvement in inpatient and emergency neurologic care. In the second part of the podcast, Dr. Teshamae Monteith focuses her interview with Dr. Randolph Evans on a Neurology Today® story about incidental findings and normal variants on brain MRI for primary headache in adults. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Vespa serves on scientific advisory boards for Intouch Health, Edge Pharmaceuticals, and Sage Pharmaceuticals; serves on editorial boards for Critical Care Medicine, Neurocritical Care, and Surgical Neurology International; has consulted for General Electric and Neuren; receives research support from NINDS; holds stock in Intouch Health and stock options in Pfizer; and gave expert testimony about brain trauma.Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH.Dr. Crowell and Dr. Evans report no disclosures.